Seeking Alpha

Analysts are bullish on Durata

  • Analysts at Roth Capital and Craig-Hallum initiate coverage of Durata Therapeutics (DRTX) with BUY ratings. Both have a price target of $20.
  • Nine analysts have ratings on the stock, seven bullish and two neutral.
  • The company's lead product is delbavancin, an IV antibacterial for adult patients with acute skin and skin structure infections caused by Gram-positive bacteria.
  • 79 mutual funds have positions, up from 68 a year earlier.
  • Shares currently exchange hands at $14.
Comments (3)
  • WalkTheTalk
    , contributor
    Comments (373) | Send Message
     
    Durata is one of the most undervalue gem I have ever seen in current Biotech companies. They have a drug candidates with solid positive clinical data to get FDA approval in an urgent needed market.

     

    Their management is proven successful team who focus on getting their drug into market and M&A their company instead of spinning salesmanship.
    6 Mar, 10:48 AM Reply Like
  • David-in-CT
    , contributor
    Comments (103) | Send Message
     
    I agree. At the end of the month, they have an AdCom Meeting:

     

    "March 31, 2014: Anti-Infective Drugs Advisory Committee Meeting Announcement
    Center Date Time Location

     

    CDER March 31, 2014 8:00 a.m. to 5:00 p.m. FDA White Oak Campus
    Building 31
    The Great Room (Rm. 1503)
    White Oak Conference Center
    10903 New Hampshire Avenue
    Silver Spring, Maryland
    -
    Agenda
    During the morning session, the committee will discuss new drug applications (NDAs) 205-435 and 205-436, tedizolid phosphate tablets and tedizolid phosphate injection, submitted by Trius Therapeutics, respectively, for the proposed indication of treatment of acute bacterial skin and skin structure infections.
    -
    During the afternoon session, the committee will discuss NDA 021-883, dalbavancin hydrochloride for intravenous injection, submitted by Durata Therapeutics International B.V., for the proposed indication of treatment of acute bacterial skin and skin structure infections."
    -
    Dalbavancin's (many) trials have been successful. By any measure, the antibiotic is well-tolerated and efficacious. You can read the trial results yourself on ClinicalTrials.gov or you can go to a service like Deepdyve and see reports on this drug over the last decade. (All were positive.)

     

    This is another weapon to use against MRSA and other nasty gram-positive bacteria. The available data convincingly argues for a 'yes' decision by the ACM with an FDA approval following. I'm not a physician, but the data is available for anyone to review. I believe everything published says this is a worthwhile drug and should be made available.
    6 Mar, 12:29 PM Reply Like
  • GrowthGeek
    , contributor
    Comments (908) | Send Message
     
    It's puzzling why Durata has not had more attention in the broader market, but it gave me the opportunity to get in cheap a couple weeks ago so I am grateful. It looks as if a lot of "smart" money knows that Dalbavancin has a superb chance of approval. I would say that it is over a 90% chance given it's trial performances (in both efficacy and safety) and the paucity of new antibiotics coming to market.
    6 Mar, 07:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|